Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 16/20 | 0.41 |
| ▸ | MMP3 | P08254 | 11/20 | 0.41 |
| ▸ | MMP1 | P03956 | 10/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MMP7 | P09237 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL415895 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Bromide SCHEMBL351568 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Bromide SCHEMBL5087862 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Bromide SCHEMBL9800687 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Bromide SCHEMBL5092892 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Bromide SCHEMBL2365613 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Bromide SCHEMBL5091440 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Bromide SCHEMBL28657602 | 0.98 | CSNK1E (0.52) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Bromide SCHEMBL28853748 | 0.98 | CSNK1E (0.52) | CSNK1EMMP2MMP3MMP1HTR2A | |
| SCHEMBL25287896 | 0.98 | CSNK1E (0.55) | CSNK1EMMP2MMP3MMP1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140178302-A1 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2014-06-26 | — | — | US | claimed |
| US-8636977-B2 | Integrin targeted synthetic ligands for diagnostic and therapeutic applications | BRACCO IMAGING S.P.A. (IT) | 2014-01-28 | — | — | US | claimed |
| US-20080317668-A1 | Integrin Targeted Synthetic Ligands for Diagnostic and Therapeutic Applications | BRACCO IMAGING S.P.A. (IT) | 2008-12-25 | — | — | US | claimed |
| EP-1853605-A2 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | Bracco Imaging, S.P.A. (IT) | 2007-11-14 | — | — | EP | claimed |
| WO-2006095234-A2 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2006-09-14 | — | — | WO | claimed |
| US-20020159952-A1 | Novel acoustically active drug delivery systems | BRISTOL-MYERS SQUIBB MEDICAL IMAGING, INC. | 2002-10-31 | — | — | US | claimed |
| US-6443898-B1 | Therapeutic delivery systems | IMARX PHARMACEUTICAL CORP. | 2002-09-03 | — | — | US | claimed |
| EP-0981333-A4 | NOVEL ACOUSTICALLY ACTIVE DRUG DELIVERY SYSTEMS | IMARX PHARMACEUTICAL CORP (US) | 2002-04-24 | — | — | EP | claimed |
| US-6071495-A | TEMPERATURE ACTIVATED; PARTICULARLY USEFUL, FOR EXAMPLE, IN ULTRASONIC IMAGING APPLICATIONS AND IN THERAPEUTIC DRUG DELIVERY SYSTEMS. | IMARX PHARMACEUTICAL CORP. (US) | 2000-06-06 | — | — | US | claimed |
| EP-0981333-A1 | NOVEL ACOUSTICALLY ACTIVE DRUG DELIVERY SYSTEMS | IMARX PHARMACEUTICAL CORP. (US) | 2000-03-01 | — | — | EP | claimed |
| US-5853752-A | Methods of preparing gas and gaseous precursor-filled microspheres | IMARX PHARMACEUTICAL CORP. (US) | 1998-12-29 | — | — | US | claimed |
| WO-1998051284-A1 | NOVEL ACOUSTICALLY ACTIVE DRUG DELIVERY SYSTEMS | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-19 | — | — | WO | claimed |
| EP-0802788-A4 | NOVEL THERAPEUTIC DELIVERY SYSTEMS | UNGER EVAN C (US) | 1998-09-09 | — | — | EP | claimed |
| EP-0712293-A4 | METHODS OF PREPARING GAS AND GASEOUS PRECURSOR-FILLED MICROSPHERES | UNGER EVAN C (US) | 1998-05-06 | — | — | EP | claimed |
| EP-0802788-A1 | NOVEL THERAPEUTIC DELIVERY SYSTEMS | UNGER, Evan C (US) | 1997-10-29 | — | — | EP | claimed |
| US-5585112-A | TEMPERATURE-ACTIVATED FLUORINE-CONTAINING GAS; USEFUL IN ULTRASONIC IMAGING AND DRUG DELIVERY SYSTEMS; FDA ORANGE BOOK LISTED PATENT FOR PERFLUTREN | IMARX PHARMACEUTICAL CORP. (US) | 1996-12-17 | — | — | US | claimed |
| EP-0712293-A1 | METHODS OF PREPARING GAS AND GASEOUS PRECURSOR-FILLED MICROSPHERES | UNGER, Evan C (US) | 1996-05-22 | — | — | EP | claimed |
| WO-1994028780-A2 | METHODS OF PREPARING GAS AND GASEOUS PRECURSOR-FILLED MICROSPHERES | UNGER EVAN C (US) | 1994-12-22 | — | — | WO | claimed |
| WO-1994028874-A1 | NOVEL THERAPEUTIC DELIVERY SYSTEMS | UNGER EVAN C (US) | 1994-12-22 | — | — | WO | claimed |
| EP-4149556-B1 | PEG LIPIDOID COMPOUNDS | TRANSLATE BIO INC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12514932-B2 | PEG lipidoid compounds | TRANSLATE BIO, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250288523-A1 | PEG LIPIDOID COMPOUNDS | TRANSLATE BIO INC (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250262334-A1 | LIPID-ENCAPSULATED GAS MICROSPHERE COMPOSITIONS AND RELATED METHODS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250230323-A1 | ENCAPSULATED CORROSION INHIBITORS | CHEMETALL GMBH (DE) | 2025-07-17 | — | — | US | disclosed |
| US-20250215237-A1 | AQUEOUS COMPOSITIONS CONTAINING ENCAPSULATED CORROSION INHIBITORS AND METHOD MAKING USE THEREOF | CHEMETALL GMBH (DE) | 2025-07-03 | — | — | US | disclosed |
| US-20250195698-A1 | GAS NANO/MICRO-BUBBLE COMPOSITIONS AND USES THEREOF | LANTHEUS MEDICAL IMAGING, INC. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250154410-A1 | COMPOSITION, AND SEMICONDUCTOR SUBSTRATE MANUFACTURING METHOD AND ETCHING METHOD USING SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2025-05-15 | — | — | US | disclosed |
| US-12296029-B2 | Lipid-encapsulated gas microsphere compositions and related methods | LANTHEUS MEDICAL IMAGING, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12280147-B2 | PEG lipidoid compounds | TRANSLATE BIO, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250121101-A1 | METHODS AND DEVICES FOR PREPARATION OF ULTRASOUND CONTRAST AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| EP-4514905-A1 | ENCAPSULATED CORROSION INHIBITORS | Chemetall GmbH (DE) | 2025-03-05 | — | — | EP | disclosed |
| EP-4514906-A1 | AQUEOUS COMPOSITIONS CONTAINING ENCAPSULATED CORROSION INHIBITORS AND METHOD MAKING USE THEREOF | Chemetall GmbH (DE) | 2025-03-05 | — | — | EP | disclosed |
| WO-2025038414-A1 | THERAPEUTIC METHODS OF USE OF GAS BUBBLE COMPOSITIONS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-4485506-A1 | COMPOSITION, AND SEMICONDUCTOR SUBSTRATE MANUFACTURING METHOD AND ETCHING METHOD USING SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2025-01-01 | — | — | EP | disclosed |
| EP-4475899-A1 | GAS NANO/MICRO-BUBBLE COMPOSITIONS AND USES THEREOF | Lantheus Medical Imaging, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| US-12097270-B2 | Methods and devices for preparation of ultrasound contrast agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2024-09-24 | — | — | US | disclosed |
| US-12061186-B2 | Compositions and methods for using cross-dressing to enhance anti-tumor immune responses | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-08-13 | — | — | US | disclosed |
| CN-118063928-A | Composite resin composition, method for producing same, insulating resin composite, and electric power device using same | 株式会社日立制作所 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024101192-A1 | COMPOSITE RESIN COMPOSITION, METHOD FOR PRODUCING SAME, INSULATING RESIN COMPLEX AND POWER APPARATUS USING SAME | 株式会社日立製作所 | 2024-05-16 | — | — | WO | disclosed |
| WO-2023208911-A1 | ENCAPSULATED CORROSION INHIBITORS | CHEMETALL GMBH (DE) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023208908-A1 | AQUEOUS COMPOSITIONS CONTAINING ENCAPSULATED CORROSION INHIBITORS AND METHOD MAKING USE THEREOF | CHEMETALL GMBH (DE) | 2023-11-02 | — | — | WO | disclosed |
| US-20230270412-A1 | METHODS AND DEVICES FOR PREPARATION OF ULTRASOUND CONTRAST AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| WO-2023163002-A1 | COMPOSITION, AND SEMICONDUCTOR SUBSTRATE MANUFACTURING METHOD AND ETCHING METHOD USING SAME | 三菱瓦斯化学株式会社 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023154828-A1 | GAS NANO/MICRO-BUBBLE COMPOSITIONS AND USES THEREOF | LANTHEUS MEDICAL IMAGING, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230226219-A1 | PEG LIPIDOID COMPOUNDS | TRANSLATE BIO, INC. | 2023-07-20 | — | — | US | disclosed |
| EP-4192611-A1 | METHODS AND DEVICES FOR PREPARATION OF ULTRASOUND CONTRAST AGENTS | Lantheus Medical Imaging, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-4154915-A1 | LIPID-ENCAPSULATED GAS MICROSPHERE COMPOSITIONS AND RELATED METHODS | Lantheus Medical Imaging, Inc. (US) | 2023-03-29 | — | — | EP | disclosed |
| EP-4149556-A1 | PEG LIPIDOID COMPOUNDS | Translate Bio, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20220395590-A1 | LIPID-ENCAPSULATED GAS MICROSPHERE COMPOSITIONS AND RELATED METHODS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| EP-3240579-B1 | LIPID-ENCAPSULATED GAS MICROSPHERE COMPOSITIONS AND RELATED METHODS | LANTHEUS MEDICAL IMAGING INC (US) | 2022-07-27 | — | — | EP | disclosed |
| US-11395856-B2 | Lipid-encapsulated gas microsphere compositions and related methods | LANTHEUS MEDICAL IMAGING, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20220071905-A1 | PEG LIPIDOID COMPOUNDS | TRANSLATE BIO, INC. | 2022-03-10 | — | — | US | disclosed |
| WO-2022031739-A1 | METHODS AND DEVICES FOR PREPARATION OF ULTRASOUND CONTRAST AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2021257623-A1 | COMPOSITIONS AND METHODS FOR USING CROSS-DRESSING TO ENHANCE ANTI-TUMOR IMMUNE RESPONSES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-12-23 | — | — | WO | disclosed |
| US-20210389301-A1 | COMPOSITIONS AND METHODS FOR USING CROSS-DRESSING TO ENHANCE ANTI-TUMOR IMMUNE RESPONSES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-12-16 | — | — | US | disclosed |
| CN-113289034-A | Lipid-encapsulated gas microsphere compositions and related methods | 蓝瑟斯医学影像公司 | 2021-08-24 | — | — | CN | disclosed |
| EP-2543706-B1 | METHOD FOR STABILIZING OF COLOR DEVELOPER AND USE THEREOF | ARKRAY INC (JP) | 2021-05-26 | — | — | EP | disclosed |
| CN-107206111-B | Lipid-encapsulated gas microsphere compositions and related methods | 蓝瑟斯医学影像公司 | 2021-04-27 | — | — | CN | disclosed |
| US-20200384132-A1 | LIPID-ENCAPSULATED GAS MICROSPHERE COMPOSITIONS AND RELATED METHODS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2020-12-10 | — | — | US | disclosed |
| US-20200171177-A1 | METHODS AND DEVICES FOR PREPARATION OF ULTRASOUND CONTRAST AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-10588988-B2 | Methods and devices for preparation of ultrasound contrast agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10583207-B2 | Lipid-encapsulated gas microsphere compositions and related methods | LANTHEUS MEDICAL IMAGING, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-10548860-B2 | HIF-1 modulator paint formulation and uses thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-02-04 | — | — | US | disclosed |
| EP-2320954-B1 | DIAGNOSTIC AGENTS SELECTIVE AGAINST METALLOPROTEASES | BRACCO IMAGING SPA (IT) | 2019-09-04 | — | — | EP | disclosed |
| US-20190192452-A1 | HIF-1 MODULATOR PAINT FORMULATION AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2019-06-27 | — | — | US | disclosed |
| EP-3452108-A2 | METHODS AND DEVICES FOR PREPARATION OF ULTRASOUND CONTRAST AGENTS | Lantheus Medical Imaging, Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10220009-B2 | HIF-1 modulator paint formulation and uses thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-03-05 | — | — | US | disclosed |
| US-10022460-B2 | Lipid-encapsulated gas microsphere compositions and related methods | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170319718-A1 | METHODS AND DEVICES FOR PREPARATION OF ULTRASOUND CONTRAST AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-11-09 | — | — | US | disclosed |
| WO-2017192910-A2 | METHODS AND DEVICES FOR PREPARATION OF ULTRASOUND CONTRAST AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| EP-3240579-A2 | LIPID-ENCAPSULATED GAS MICROSPHERE COMPOSITIONS AND RELATED METHODS | Lantheus Medical Imaging, Inc. (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20170258946-A1 | LIPID-ENCAPSULATED GAS MICROSPHERE COMPOSITIONS AND RELATED METHODS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20160331851-A1 | LIPID-ENCAPSULATED GAS MICROSPHERE COMPOSITIONS AND RELATED METHODS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-9493605-B2 | Epoxy-vinyl copolymerization type liquid resin composition, cured product of the same, electronic/electric apparatus using the cured product, and method of producing the cured product | HITACHI INDUSTRIAL EQUIPMENT SYSTEMS CO., LTD. (JP) | 2016-11-15 | — | — | US | disclosed |
| US-9480758-B2 | Diagnostic agents selective against metalloproteases | BRACCO IMAGING S.P.A. (IT) | 2016-11-01 | — | — | US | disclosed |
| US-9409951-B2 | Integrin targeted synthetic ligands for diagnostic and therapeutic applications | BRACCO IMAGING S.P.A. (IT) | 2016-08-09 | — | — | US | disclosed |
| US-9334161-B2 | Processing liquid for suppressing pattern collapse of fine metal structure and method for producing fine metal structure using same | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2016-05-10 | — | — | US | disclosed |
| US-20150196512-A1 | HIF-1 Modulator Paint Formulation and Uses Thereof | THE JOHNS HOPKINS UNIVERSITY | 2015-07-16 | — | — | US | disclosed |
| EP-2851382-A1 | EPOXY/VINYL COPOLYMER-TYPE LIQUID RESIN COMPOSITION, CURED ARTICLE THEREOF, ELECTRICAL/ELECTRONIC DEVICE USING SAID CURED ARTICLE, AND METHOD FOR PRODUCING SAID CURED ARTICLE | Hitachi Industrial Equipment Systems Co., Ltd. (JP) | 2015-03-25 | — | — | EP | disclosed |
| US-20140378580-A1 | Epoxy-Vinyl Copolymerization Type Liquid Resin Composition, Cured Product of the Same, Electronic/Electric Apparatus using the Cured Product, and Method of Producing the Cured Product | HITACHI INDUSTRIAL EQUIPMENT SYSTEMS CO., LTD. (JP) | 2014-12-25 | — | — | US | disclosed |
| EP-1853605-B1 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING SPA (IT) | 2014-09-10 | — | — | EP | disclosed |
| EP-2603238-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AN OCULAR DISEASE IN A SUBJECT | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2014-07-30 | — | — | EP | disclosed |
| US-20140178302-A1 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2014-06-26 | — | — | US | disclosed |
| US-8758648-B2 | Stabilizer of color former and use thereof | ARKRAY, INC. (JP) | 2014-06-24 | — | — | US | disclosed |
| WO-2014036414-A2 | IRON CHELATORS AND USE THEREOF FOR REDUCING TRANSPLANT FAILURE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-03-06 | — | — | WO | disclosed |
| US-8636977-B2 | Integrin targeted synthetic ligands for diagnostic and therapeutic applications | BRACCO IMAGING S.P.A. (IT) | 2014-01-28 | — | — | US | disclosed |
| US-20130261535-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AN OCULAR DISEASE IN A SUBJECT | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2013-10-03 | — | — | US | disclosed |
| US-20130199599-A1 | POLYESTER FILM, BACK SHEET FOR SOLAR CELL, AND SOLAR CELL MODULE | FUJIFILM CORPORATION (JP) | 2013-08-08 | — | — | US | disclosed |
| EP-2603238-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AN OCULAR DISEASE IN A SUBJECT | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2013-06-19 | — | — | EP | disclosed |
| US-8454937-B2 | microbubbles comprising gases and DNA viruses comprising an expression cassette that code for green fluorescent protein, luciferase, chloramphenicol transferase, beta -glucuronidase or beta -galactosidase, encapsulated in protein or phosphatide shells; drug delivery; tissue-targeted therapy | Temple University—Of The Commonwealth System of High Education (US) | 2013-06-04 | — | — | US | disclosed |
| EP-2543706-A2 | Stabilizer of color former and use thereof | ARKRAY, Inc. (JP) | 2013-01-09 | — | — | EP | disclosed |
| US-20120181249-A1 | PROCESSING LIQUID FOR SUPPRESSING PATTERN COLLAPSE OF FINE METAL STRUCTURE AND METHOD FOR PRODUCING FINE METAL STRUCTURE USING SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2012-07-19 | — | — | US | disclosed |
| WO-2012095516-A1 | HUMAN ANTIBODIES CROSS-REACTING WITH A BACTERIAL AND A SELF ANTIGEN FROM ATHEROSCLEROTIC PLAQUES | BRACCO IMAGING SPA (IT) | 2012-07-19 | — | — | WO | disclosed |
| EP-2476703-A1 | Human antibodies cross-reacting with a bacterial and a self antigen from atherosclerotic plaques | Bracco Imaging S.p.A (IT) | 2012-07-18 | — | — | EP | disclosed |
| US-20120165211-A1 | Human Antibodies Cross-Reacting With A Bacterial And A Self Antigen From Atherosclerotic Plaques | BRACCO IMAGING S.P.A. (IT) | 2012-06-28 | — | — | US | disclosed |
| WO-2012020001-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AN OCULAR DISEASE IN A SUBJECT | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2012-02-16 | — | — | WO | disclosed |
| US-20120021036-A1 | COMPOSITE NANOSTRUCTURES AND METHODS FOR MAKING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110117015-A1 | Diagnostic Agents Selective Against Metalloproteases | BRACCO IMAGING S.P.A. (IT) | 2011-05-19 | — | — | US | disclosed |
| EP-2320954-A1 | DIAGNOSTIC AGENTS SELECTIVE AGAINST METALLOPROTEASES | Bracco Imaging S.p.A (IT) | 2011-05-18 | — | — | EP | disclosed |
| US-20110015391-A1 | STABILIZER OF COLOR FORMER AND USE THEREOF | ARKRAY, INC. (JP) | 2011-01-20 | — | — | US | disclosed |
| EP-2270105-A1 | STABILIZER FOR COLOR DEVELOPER AND USE THEREOF | ARKRAY, Inc. (JP) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010083337-A2 | COMPOSITE NANOSTRUCTURES AND METHODS FOR MAKING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORINIA (US) | 2010-07-22 | — | — | WO | disclosed |
| EP-1294422-B1 | Medical System for Reducing Vascular Occlusions | CORDIS CORP (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2010010079-A1 | DIAGNOSTIC AGENTS SELECTIVE AGAINST METALLOPROTEASES | BRACCO IMAGING SPA (IT) | 2010-01-28 | — | — | WO | disclosed |
| EP-2147684-A1 | Diagnostic Agents Selective Against Metalloproteases | Bracco Imaging S.p.A (IT) | 2010-01-27 | — | — | EP | disclosed |
| EP-1588699-B1 | Gas-filled liposomes comprising an insoluble gas in combination with a soluble gas | LANTHEUS MEDICAL IMAGING INC (US) | 2009-10-14 | — | — | EP | disclosed |
| EP-2075031-A1 | Methods and systems for enhancing fluid flow trough an obstructed vascular site | Corazon Technologies, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20080317668-A1 | Integrin Targeted Synthetic Ligands for Diagnostic and Therapeutic Applications | BRACCO IMAGING S.P.A. (IT) | 2008-12-25 | — | — | US | disclosed |
| US-20080319375-A1 | Materials, Methods, and Systems for Cavitation-mediated Ultrasonic Drug Delivery in vivo | BIOVALUATION & ANALYSIS, INC. | 2008-12-25 | — | — | US | disclosed |
| WO-2008157422-A1 | MATERIALS, METHODS, AND SYSTEMS FOR CAVITATION-MEDIATED ULTRASONIC DRUG DELIVERY | HARDY CHARLES THOMAS (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080312581-A1 | Peptosomes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo | BIOVALUATION & ANALYSIS, INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080311045-A1 | Polymersomes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo | BIOVALUATION & ANALYSIS, INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080299177-A1 | Supramolecular Complexes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo | BIOVALUATION & ANALYSIS, INC. | 2008-12-04 | — | — | US | disclosed |
| US-20080294089-A1 | Dendritic Polymers for Use in Acoustically Mediated Intracellular Drug Delivery in vivo | BIOVALUATION & ANALYSIS, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080243049-A1 | Biodegradable Triblock Copolymers for Use in Acoustically Mediated Intracellular Drug Delivery in vivo | BIOVALUATION & ANALYSIS, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080214386-A1 | Stability; easily separated from solution; surface treatment of catalyst with Group seven compound; reacting epoxide with carbon dioxide | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2008-09-04 | — | — | US | disclosed |
| US-20080063604-A1 | Method and composition for the site-selective gene delivery using viruses | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-03-13 | — | — | US | disclosed |
| EP-1853605-A2 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | Bracco Imaging, S.P.A. (IT) | 2007-11-14 | — | — | EP | disclosed |
| US-20070196462-A1 | Composition and method for neuromuscular blockade | IMARX THERAPEUTICS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2007087418-A2 | COMPOSITION AND METHOD FOR NEUROMUSCULAR BLOCKADE | IMARX THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070173784-A1 | Methods for enhancing fluid flow through an obstructed vascular site, and systems and kits for use in practicing the same | CORDIS US CORP | 2007-07-26 | — | — | US | disclosed |
| EP-1294422-A4 | METHODS AND SYSTEMS FOR ENHANCING FLUID FLOW THROUGH AN OBSTRUCTED VASCULAR SITE | CORAZON TECHNOLOGIES INC (US) | 2007-02-21 | — | — | EP | disclosed |
| US-7179446-B2 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-7141045-B2 | Methods for enhancing fluid flow through an obstructed vascular site, and systems and kits for use in practicing the same | CORAZON TECHNOLOGIES, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| WO-2006095234-A2 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2006-09-14 | — | — | WO | disclosed |
| US-7052673-B2 | Pharmaceuticals for the imaging of angiogenic disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060003926-A1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | LANTHEUS MEDICAL IMAGING, INC. | 2006-01-05 | — | — | US | disclosed |
| EP-1588699-A2 | Container with multi-phase composition for use in diagnostic and therapeutic applications | IMARX PHARMACEUTICAL CORP. (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050118100-A9 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | LANTHEUS MEDICAL IMAGING, INC. | 2005-06-02 | — | — | US | disclosed |
| EP-1068224-B1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-05-11 | — | — | EP | disclosed |
| US-6818659-B2 | TARGETS AND BINDS BIOLOGICAL RECEPTORS; MEDICAL DIAGNOSIS; MAGNETIC RESONANCE, X-RAY, ULTRASOUND, AND CONTRAST IMAGING | BRISTOL-MYERS SQUIBB PHARMA, INC. | 2004-11-16 | — | — | US | disclosed |
| US-6800273-B2 | ANTICANCER AGENTS; ANGIOGENOSIS INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-10-05 | — | — | US | disclosed |
| EP-0788348-B1 | CONTAINER WITH MULTI-PHASE COMPOSITION FOR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | IMARX PHARMACEUTICAL CORP (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20040087603-A1 | (2S) -2-AMINO-4-(2-AMINO-(3,4,5,6-TETRAHYDROPYRIMIDIN-4-YL) BUTANOYL AND ITS USE IN CYCLIC AND ACYCLIC PEPTIDES | LANTHEUS MEDICAL IMAGING, INC. | 2004-05-06 | — | — | US | disclosed |
| US-20040077773-A1 | Low viscosity, flexible, hydrolytically stable potting compounds | LORD CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20030180305-A1 | Pharmaceuticals for the imaging of angiogenic disorders | LANTHEUS MEDICAL IMAGING, INC. | 2003-09-25 | — | — | US | disclosed |
| EP-1337278-A2 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | Bristol-Myers Squibb Medical Imaging, Inc. (US) | 2003-08-27 | — | — | EP | disclosed |
| EP-0840570-B1 | APPARATUS AND METHOD FOR MAKING GAS-FILLED VESICLES OF OPTIMAL SIZE | IMARX PHARMACEUTICAL CORP (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20030104073-A1 | Methods for enhancing fluid flow through an obstructed vascular site, and systems and kits for use in practicing the same | CORDIS US CORP | 2003-06-05 | — | — | US | disclosed |
| EP-1311302-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | Bristol-Myers Squibb Pharma Company (US) | 2003-05-21 | — | — | EP | disclosed |
| US-6551576-B1 | Container of a single perfluorocarbon gas, and an aqueous lipid suspension phase comprises a phosphatidyl choline, phosphatidylethanolamine, and/or a phosphatidic acid; use in diagnostic imaging; magnetic resonance imaging | BRISTOL-MYERS SQUIBB MEDICAL IMAGING, INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1294422-A1 | METHODS AND SYSTEMS FOR ENHANCING FLUID FLOW THROUGH AN OBSTRUCTED VASCULAR SITE | Corazon Technologies, Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6537520-B1 | Diagnosis and treatment of cancer; kit containing compound having peptide or peptidomimetic functionality that binds to a alpha v beta 3 receptor linked to a chelator | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-03-25 | — | — | US | disclosed |
| US-6533767-B2 | Methods for enhancing fluid flow through an obstructed vascular site, and systems and kits for use in practicing the same | CORAZON TECHNOLOGIES, INC. | 2003-03-18 | — | — | US | disclosed |
| US-6488671-B1 | Methods for enhancing fluid flow through an obstructed vascular site, and systems and kits for use in practicing the same | CORAZON TECHNOLOGIES, INC. | 2002-12-03 | — | — | US | disclosed |
| EP-1252885-A2 | Methods of preparing gas and gaseous precursor-filled microspheres | IMARX PHARMACEUTICAL CORP. (US) | 2002-10-30 | — | — | EP | disclosed |
| EP-0839125-A4 | NOVEL CATIONIC LIPIDS AND THE USE THEREOF | IMARX PHARMACEUTICAL CORP (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020106325-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | CARPENTER ALAN P (US) | 2002-08-08 | — | — | US | disclosed |
| WO-2002055111-A2 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | BRISTOL MYERS SQUIBB MEDICAL I (US) | 2002-07-18 | — | — | WO | disclosed |
| EP-0662097-B1 | POLYMER COMPOSITION | MONSANTO CO (US) | 2002-05-22 | — | — | EP | disclosed |
| US-20020001566-A1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-03 | — | — | US | disclosed |
| WO-2001097860-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS FOR USE IN COMBINATION THERAPY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
| US-20010039411-A1 | Methods for enhancing fluid flow through an obstructed vascular site, and systems and kits for use in practicing the same | CORDIS US CORP | 2001-11-08 | — | — | US | disclosed |
| WO-2001070320-A1 | METHODS AND SYSTEMS FOR ENHANCING FLUID FLOW THROUGH AN OBSTRUCTED VASCULAR SITE | CORAZON TECHNOLOGIES, INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-0840570-A4 | APPARATUS AND METHOD FOR MAKING GAS-FILLED VESICLES OF OPTIMAL SIZE | IMARX PHARMACEUTICAL CORP (US) | 2001-05-30 | — | — | EP | disclosed |
| EP-1068224-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | Du Pont Pharmaceuticals Company (US) | 2001-01-17 | — | — | EP | disclosed |
| US-6146657-A | LIPOSOME FILLED WITH AN INSOLUBLE GAS AND A SOLUBLE GAS, WHEREIN SAID LIPOSOME COMPRISES PHOSPHATIDYLCHOLINE(S), PHOSPHATIDYLETHANOLAMINE(S), AND PHOSPHATIDIC ACID(S); USE IN ULTRASONIC OR MAGNETIC RESONANCE IMAGING | IMARX PHARMACEUTICAL CORP. (US) | 2000-11-14 | — | — | US | disclosed |
| US-6056938-A | Cationic lipids and the use thereof | IMARX PHARACEUTICAL CORP. (US) | 2000-05-02 | — | — | US | disclosed |
| US-6039557-A | Apparatus for making gas-filled vesicles of optimal size | IMARX PHARMACEUTICAL CORP. (US) | 2000-03-21 | — | — | US | disclosed |
| WO-1999058162-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-11-18 | — | — | WO | disclosed |
| US-5830430-A | Cationic lipids and the use thereof | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-03 | — | — | US | disclosed |
| US-5773024-A | LIPOSOMES | IMARX PHARMACEUTICAL CORP. (US) | 1998-06-30 | — | — | US | disclosed |
| EP-0840570-A2 | APPARATUS AND METHOD FOR MAKING GAS-FILLED VESICLES OF OPTIMAL SIZE | IMARx PHARMACEUTICAL CORP. (US) | 1998-05-13 | — | — | EP | disclosed |
| EP-0839125-A1 | NOVEL CATIONIC LIPIDS AND THE USE THEREOF | IMARX PHARMACEUTICAL CORP. (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0602647-B1 | Superconducting magnet, superconducting magnet coil, and manufacturing method thereof | HITACHI LTD (JP) | 1998-04-29 | — | — | EP | disclosed |
| EP-0788348-A4 | CONTAINER WITH MULTI-PHASE COMPOSITION FOR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | IMARX PHARMACEUTICAL CORP (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0788348-A1 | CONTAINER WITH MULTI-PHASE COMPOSITION FOR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | IMARX PHARMACEUTICAL CORP. (US) | 1997-08-13 | — | — | EP | disclosed |
| US-5656350-A | Coil impregnant of epoxy resin from polyhydric phenol mixture | HITACHI, LTD. (JP) | 1997-08-12 | — | — | US | disclosed |
| US-5656211-A | RECIPROCATING MOTION SHAKING OF AQUEOUS SUSPENSION AND GAS IN CLOSED CONTAINER | IMARX PHARMACEUTICAL CORP. (US) | 1997-08-12 | — | — | US | disclosed |
| EP-0488275-B1 | Resin-impregnated superconducting magnet coil and process for its production | HITACHI LTD (JP) | 1997-04-02 | — | — | EP | disclosed |
| US-5606300-A | FIXING RESIN WHICH SUPPRESSES MICROCRACKING | HITACHI, LTD. (JP) | 1997-02-25 | — | — | US | disclosed |
| US-5599891-A | CRYSTALLISABLE, BIODEGRADABLE POLYHYDROXYALKANOATE, HAVING ON THEIR SURFACE A PHOPHOLIPID OR A SURFACTANT | ZENECA LIMITED (GB) | 1997-02-04 | — | — | US | disclosed |
| WO-1997000638-A2 | APPARATUS AND METHOD FOR MAKING GAS-FILLED VESICLES OF OPTIMAL SIZE | IMARX PHARMACEUTICAL CORP. (US) | 1997-01-09 | — | — | WO | disclosed |
| WO-1996026179-A1 | NOVEL CATIONIC LIPIDS AND THE USE THEREOF | IMARX PHARMACEUTICAL CORP. (US) | 1996-08-29 | — | — | WO | disclosed |
| US-5538942-A | EPOXY RESIN | HITACHI, LTD. (JP) | 1996-07-23 | — | — | US | disclosed |
| WO-1996008234-A1 | CONTAINER WITH MULTI-PHASE COMPOSITION FOR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | IMARX PHARMACEUTICAL CORP. (US) | 1996-03-21 | — | — | WO | disclosed |
| EP-0662097-A1 | POLYMER COMPOSITION | MONSANTO COMPANY (US) | 1995-07-12 | — | — | EP | disclosed |
| US-5393805-A | Coil for use in concrete including electric conductor molded in cured resin derived from polyfunctional epoxy resin, latent curing catalyst, alkali resistant filler, surfactant | HITACHI, LTD. (JP) | 1995-02-28 | — | — | US | disclosed |
| US-5384197-A | Impregnated polyepoxide resin | HITACHI, LTD. (JP) | 1995-01-24 | — | — | US | disclosed |
| US-5324767-A | Thermosetting resin composition for casting high-voltage coil, and molded coil and panel formed by casting and curing the composition | HITACHI, LTD. (JP) | 1994-06-28 | — | — | US | disclosed |
| EP-0602647-A1 | Superconducting magnet, superconducting magnet coil, and manufacturing method thereof | HITACHI, LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| WO-1994007940-A1 | POLYMER COMPOSITION | ZENECA LIMITED (GB) | 1994-04-14 | — | — | WO | disclosed |
| EP-0488275-A2 | Resin-impregnated superconducting magnet coil and process for it production | HITACHI, LTD. (JP) | 1992-06-03 | — | — | EP | disclosed |
| US-5075159-A | Binding polyfunctional epoxy resin, impregnation bifunctional epoxy resin | KOYAMA TOHRU (JP) | 1991-12-24 | — | — | US | disclosed |
| EP-0413179-A2 | Electrically insulated coil, electric rotating machine, and method of manufacturing same | HITACHI, LTD. (JP) | 1991-02-20 | — | — | EP | disclosed |
| US-4692540-A | Process for the preparation of cyclic phosphites | CIBA-GEIGY CORPORATION (US) | 1987-09-08 | — | — | US | disclosed |
| US-4692540-A | Process for the preparation of cyclic phosphites | CIBA-GEIGY CORPORATION (US) | 1987-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12280147-B2 | PEG lipidoid compounds | HDLBP, LIPG, ABCB4 | CSNK1E 2548/4885MMP2 3079/4885MMP3 4296/4885 |
| US-20250288523-A1 | PEG LIPIDOID COMPOUNDS | LIPG, ABCB4, HDLBP | CSNK1E 2506/4885MMP2 2921/4885MMP3 4144/4885 |
| US-20020159952-A1 | Novel acoustically active drug delivery systems | AURKA, AURKC, MTDH | CSNK1E 3959/4885MMP2 1940/4885MMP3 2667/4885 |
| US-20050118100-A9 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | TNNI3, ASGR1, TNNT2 | CSNK1E 4674/4885MMP2 2837/4885MMP3 1993/4885 |
| US-20020106325-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | TNNI3, ASGR1, TNNT2 | CSNK1E 4674/4885MMP2 2837/4885MMP3 1993/4885 |
| US-20220071905-A1 | PEG LIPIDOID COMPOUNDS | HDLBP, LIPG, ABCB4 | CSNK1E 2548/4885MMP2 3079/4885MMP3 4296/4885 |
| US-20110117015-A1 | Diagnostic Agents Selective Against Metalloproteases | MMP3, MMP7, MMP9 | CSNK1E 2395/4885MMP2 9/4885MMP3 1/4885 |
| US-20030104073-A1 | Methods for enhancing fluid flow through an obstructed vascular site, and systems and kits for use in practicing the same | CA2, DUOX2, SMOX | CSNK1E 3513/4885MMP2 250/4885MMP3 161/4885 |
| US-20020001566-A1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | VEGFA, FLT4, FLT1 | CSNK1E 1894/4885MMP2 2527/4885MMP3 1508/4885 |
| US-20080312581-A1 | Peptosomes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo | MYOC, PITRM1, VIP | CSNK1E 4543/4885MMP2 3335/4885MMP3 3045/4885 |
| US-20120165211-A1 | Human Antibodies Cross-Reacting With A Bacterial And A Self Antigen From Atherosclerotic Plaques | TAGLN2, TTN, TXLNA | CSNK1E 1739/4885MMP2 2715/4885MMP3 3614/4885 |
| US-20040087603-A1 | (2S) -2-AMINO-4-(2-AMINO-(3,4,5,6-TETRAHYDROPYRIMIDIN-4-YL) BUTANOYL AND ITS USE IN CYCLIC AND ACYCLIC PEPTIDES | VIP, ARGLU1, NGLY1 | CSNK1E 2739/4885MMP2 2559/4885MMP3 3199/4885 |
| US-20140178302-A1 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | ITGA2B, ITGB2, ITGB1 | CSNK1E 1023/4885MMP2 3084/4885MMP3 3451/4885 |
| US-20230226219-A1 | PEG LIPIDOID COMPOUNDS | LIPG, ABCB4, HDLBP | CSNK1E 2506/4885MMP2 2921/4885MMP3 4144/4885 |
| US-20060003926-A1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | FLT4, VEGFA, FLT1 | CSNK1E 2418/4885MMP2 2975/4885MMP3 1315/4885 |
| US-20030180305-A1 | Pharmaceuticals for the imaging of angiogenic disorders | VEGFA, FLT4, FLT1 | CSNK1E 1894/4885MMP2 2527/4885MMP3 1508/4885 |
| US-20110015391-A1 | STABILIZER OF COLOR FORMER AND USE THEREOF | TYR, CRYZ, MITF | CSNK1E 1300/4885MMP2 1726/4885MMP3 2063/4885 |
| US-20080317668-A1 | Integrin Targeted Synthetic Ligands for Diagnostic and Therapeutic Applications | ITGA2B, ITGB2, ITGB1 | CSNK1E 1023/4885MMP2 3084/4885MMP3 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.